PMID- 35327495
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220329
IS  - 2227-9059 (Print)
IS  - 2227-9059 (Electronic)
IS  - 2227-9059 (Linking)
VI  - 10
IP  - 3
DP  - 2022 Mar 17
TI  - Proteomic Profiling and T Cell Receptor Usage of Abacavir Susceptible Subjects.
LID - 10.3390/biomedicines10030693 [doi]
LID - 693
AB  - Type B adverse drug reactions (ADRs) represent a significant threat as their 
      occurrence arises unpredictable and despite proper application of the drug. The 
      severe immune reaction Abacavir Hypersensitivity Syndrome (AHS) that arises in 
      HIV(+) patients treated with the antiretroviral drug Abacavir (ABC) strongly 
      correlates to the presence of the human leukocyte antigen (HLA) genotype 
      HLA-B*57:01 and discriminates HLA-B*57:01(+) HIV(+) patients from ABC treatment. 
      However, not all HLA-B*57:01(+) HIV(+) patients are affected by AHS, implying the 
      involvement of further patient-specific factors in the development of AHS. The 
      establishment of a reliable assay to classify HLA-B*57:01 carriers as ABC 
      sensitive or ABC tolerant allowed to investigate the T cell receptor (TCR) Vbeta 
      chain repertoire of effector cells and revealed Vbeta6 and Vbeta24 as potential public 
      TCRs in ABC sensitive HLA-B*57:01 carriers. Furthermore, distinct effects of ABC 
      on the cellular proteome of ABC sensitive and tolerant volunteers were observed 
      and suggest enhanced activation and maturation of dentritic cells (DC) in ABC 
      sensitive volunteers. Analysis of ABC-naive cellular proteomes identified the T 
      cell immune regulator 1 (TCIRG1) as a potential prognostic biomarker for ABC 
      susceptibility and the involvement of significantly upregulated proteins, 
      particularly in peptide processing, antigen presentation, interferon (IFN), and 
      cytokine regulation.
FAU - Gall, Eline
AU  - Gall E
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Stieglitz, Florian
AU  - Stieglitz F
AUID- ORCID: 0000-0001-8799-560X
AD  - Institute of Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
AD  - Core Facility Proteomics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
FAU - Pich, Andreas
AU  - Pich A
AUID- ORCID: 0000-0001-8444-0940
AD  - Institute of Toxicology, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
AD  - Core Facility Proteomics, Hannover Medical School, Carl-Neuberg-Str. 1, 30625 
      Hannover, Germany.
FAU - Behrens, Georg Martin Norbert
AU  - Behrens GMN
AUID- ORCID: 0000-0003-3111-621X
AD  - Department for Rheumatology and Immunology, Hannover Medical School, 
      Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
AD  - German Center for Infection Research (DZIF), Partner Site Hannover-Braunschweig, 
      Inhoffenstr. 7, 38124 Braunschweig, Germany.
FAU - Kuhn, Joachim
AU  - Kuhn J
AD  - Heart and Diabetes Center North Rhine-Westphalia, Institute for Laboratory and 
      Transfusion Medicine, Ruhr University Bochum, Georgstr. 11, 32545 Bad Oeynhausen, 
      Germany.
FAU - Blasczyk, Rainer
AU  - Blasczyk R
AUID- ORCID: 0000-0003-3875-3190
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Haukamp, Funmilola Josephine
AU  - Haukamp FJ
AUID- ORCID: 0000-0003-4076-821X
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
FAU - Bade-Doding, Christina
AU  - Bade-Doding C
AUID- ORCID: 0000-0002-5826-1989
AD  - Institute for Transfusion Medicine and Transplantat Engineering, Hannover Medical 
      School, Carl-Neuberg-Str. 1, 30625 Hannover, Germany.
LA  - eng
GR  - MED1912/Hector-Stiftung/
PT  - Journal Article
DEP - 20220317
PL  - Switzerland
TA  - Biomedicines
JT  - Biomedicines
JID - 101691304
PMC - PMC8945713
OTO - NOTNLM
OT  - HLA-B*57:01
OT  - T cell receptor
OT  - abacavir
OT  - adverse drug reaction
OT  - hypersensitivity
OT  - proteome
COIS- The authors declare no conflict of interest.
EDAT- 2022/03/26 06:00
MHDA- 2022/03/26 06:01
PMCR- 2022/03/17
CRDT- 2022/03/25 01:04
PHST- 2022/01/12 00:00 [received]
PHST- 2022/03/16 00:00 [revised]
PHST- 2022/03/16 00:00 [accepted]
PHST- 2022/03/25 01:04 [entrez]
PHST- 2022/03/26 06:00 [pubmed]
PHST- 2022/03/26 06:01 [medline]
PHST- 2022/03/17 00:00 [pmc-release]
AID - biomedicines10030693 [pii]
AID - biomedicines-10-00693 [pii]
AID - 10.3390/biomedicines10030693 [doi]
PST - epublish
SO  - Biomedicines. 2022 Mar 17;10(3):693. doi: 10.3390/biomedicines10030693.